For all news and media-related matters, please contact Fintan Steele, Ph.D., Executive Director of Communications, at 720-214-3080 or by email.
___________________
AAAS 2012 Annual Meeting features talk about SOMAscan technology in "Predictive Medicine"
2-17-2012
“Prediction” is only part of what is needed to realize the promise of personalized medicine: It is perhaps more critical to detect the early onset of disease in real time, when it is most likely to be successfully treated. Dr. Larry Gold, CEO of SomaLogic and Professor at the University of Colorado Boulder, presented SomaLogic's breakthrough SOMAscan proteomic technology – which promises to provide such sensitive and early detection, and ultimately transform the practice of medicine – at a special Session on “Predictive Medicine” on February 17, 2012, at the American Association for the Advancement of Science (AAAS) annual meeting in Vancouver, Canada.
The full press release is available here or as a downloadable PDF.
___________________
SomaLogic receives Gates Foundation Grand Challenges Tuberculosis Biomarkers Grant
2-9-2012
SomaLogic, Inc., announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation’s Grand Challenges in Global Health program, an initiative that seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. Urs Ochsner, head of the Infectious Diseases Research Group at SomaLogic, will pursue an innovative research project to identify and validate TB biomarkers, titled SOMAmer-based detection of tuberculosis biomarkers.
The full press release is available here or as a downloadable PDF.
The Gates Foundation press release is available here.
____________________
SomaLogic scientists to present SOMAscan technology and multiple applications at the 2012 Molecular Medicine Tri-Conference
2-9-2012
With the recent successful commercial launch of its powerful protein biomarker SOMAscan™ assay as a service to biopharmaceutical researchers, SomaLogic scientists will be presenting both the “nuts and bolts” of the technology as well as its multiple therapeutic and diagnostic applications to over 3000 participants at the 2012 Molecular Medicine Tri-Conference February 19-23 in San Francisco, CA.
The full press release is available here or as a downloadable PDF.
____________________
SomaLogic announces collaboration with Novartis
10-18-2011
SomaLogic and Novartis have entered into a multiyear research collaboration to bring SomaLogic's proteomic technology to bear on accelerating Novartis' research and development efforts, by identifying novel biomarkers, therapeutic targets, and physiological effects of potential new drugs. The agreement includes the potential for joint development of companion diagnostics arising from the collaborative effort.
The full press release is available here or as a downloadable PDF.
____________________
SOMAscanTM technology now available to to researchers via SOMAscan StandardTM
10-18-2011
SomaLogic is now offering private and public research groups early access to its powerful SOMAmer-based technology, on a fee-for-service basis. Our early-access offering is called SOMAscan Standard, an array that consists of 300 specific SOMAmers that bind proteins of general interest. More information can be found in the Services section of our website.